Navigation Links
BioElectronics' ActiPatch Reduces Muscle Soreness in Runners
Date:5/7/2012

FREDERICK, Md., May 7, 2012 /PRNewswire/ -- BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, inexpensive drug-free topical pain and healing devices, today announced the completion of a randomized, controlled trial on delayed muscle onset soreness using BIEL's ActiPatch® product.  ActiPatch uses pulsed electromagnetic field therapy to reduce pain, inflammation, and promote the healing of injured tissue.

A double blind, randomized, placebo controlled trial on delayed onset muscle soreness after marathon running found that ActiPatch® significantly reduces muscle soreness in the thighs in  runners, in the days after the completion of a marathon, compared to runners who used a placebo device. There was also a strong trend to increased running activity post marathon, which was significant on the first day after the marathon. This research study is now under peer review for publication, and the results will also be presented at EFORT (European Federation of National Associations of Orthopaedics and Traumatology) conference in Berlin, May 2012. The principle investigator leading the research was Dr. Rasmussen, Associate Professor Director of Research, Aarhus University Hospital, Aalborg Hospital, Denmark.

This study also confirms the results in the previous US muscle onset soreness study wherein ActiPatch® showed superior, and statistically significant pain relief compared to the OTC drug, acetaminophen. It has been forwarded to the FDA to support the Company's ActiPatch® application for relief of musculoskeletal pain. 

"We are delighted about the completion of this second randomized control trial on delayed muscle onset soreness," said Ian Rawe, Ph.D., BioElectronics Director of Clinical Research. "There are currently no interventions that can effectively alleviate muscle soreness, and certainly none that allow for quicker return to physical activity. These results suggest that BioElectronics' ActiPatch® device has the potential to be widely used in sports applications, not just for injury recovery but also injury prevention and improved performance. The exposure of these results and our technology at the EFORT conference, presented by a respected researcher, will be extremely beneficial, and in due course will attract more research in this interesting field."

"The fact that these research initiatives have been independently undertaken show that our technology is becoming widely accepted by the medical community," said Andrew Whelan, CEO.

About BioElectronics Corporation

BioElectronics is an award winning developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.

Contact:  E & E Communications
Paul Knopick
(949) 707-5365


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioElectronics Announces Major Clinical Trials
2. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
3. BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date
4. YesDTC Holdings and BioElectronics Receive Japanese Regulatory Review Date
5. BioElectronics Corporation to Webcast, Live, at RetailInvestorConferences.com on October 6th
6. BioElectronics Study on Plantar Fasciitis to be Published in The Journal of Foot and Ankle Surgery
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
9. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
10. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
11. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):